About Contact Us Careers

Neuralgia Drugs Market Size & Share, by Type (Anticonvulsants, Antidepressants, Opioids); Distribution Channel (Hospital Pharmacies, Retail Pharmacies, Online Pharmacies) - Global Supply & Demand Analysis, Growth Forecasts, Statistics Report 2025-2037

  • Report ID: 3469
  • Published Date: Dec 24, 2024
  • Report Format: PDF, PPT

Global Market Size, Forecast, and Trend Highlights Over 2025-2037

Neuralgia Drugs Market size is poised to grow at over 6.3% CAGR during the forecast period i.e., between 2025-2037.

The growth of the market can be attributed to the growing prevalence of trigeminal neuralgia, increasing incidence rate of diabetes around the world, and rise in occurrence of diseases such as multiple sclerosis. According to the World Health Organization (WHO), 422 million people worldwide are suffering from diabetes, out of which 1.6 million people succumb to this disease every year. Along with these, rapidly growing geriatric population since the last two decades and rising governmental support regarding the manufacture of post herpetic neuralgia treatment products are also expected to drive market growth in the upcoming years. Furthermore, surge in development of healthcare infrastructure worldwide coupled with escalating disposable income of the global population are projected to provide profitable opportunities for market growth in the near future.

Growth Drivers

  • Growing Prevalence of Trigeminal Neuralgia
  • Increasing Incidence Rate of Diabetes Around the World

Challenges

  • Poor Efficacy of Several Available Neuralgia Drugs

Access Detailed Forecasts & Data-Driven Insights: Request Free Sample PDF

Neuralgia Drugs Segmentation

The market is segmented by distribution channel into hospital pharmacies, retail pharmacies, online pharmacies, and others, out of which, the hospital pharmacies segment is anticipated to hold the largest share in the market on account of the fact that frequent interactions of prescriber and other health professionals are promoted in a hospital facility, and it offers improved input in making efficient drugs related decisions. Additionally, on the basis of type, the segment for anticonvulsants is estimated to acquire the largest share during the forecast period, which can be credited to the high usage of carbamazepine, which is an anticonvulsant, for the initial treatment of trigeminal neuralgia across the globe. Apart from these, effectiveness of these drugs in calming hyperactivity in the brain is also predicted to boost the growth of the market segment in the future. 

Our in-depth analysis of the global market includes the following segments:

           By Type
  • Anticonvulsants
  • Antidepressants
  • Opioids

             By Distribution Channel
  • Hospital Pharmacies
  • Retail Pharmacies
  • Online Pharmacies
  • Others
Vishnu Nair
Vishnu Nair
Head - Global Business Development

Customize this report to your requirements — connect with our consultant for personalized insights and options.

Neuralgia Drugs Industry - Regional Synopsis

On the basis of geographical analysis, the neuralgia drugs market is segmented into five major regions including North America, Europe, Asia Pacific, Latin America and the Middle East & Africa region. Asia Pacific industry is likely to hold largest revenue share by 2037, on the back of increasing occurrence of diabetes and rising elderly population in the region. In addition, growing development of large specialty hospitals in countries namely China and India, is also projected to drive the region’s market growth in the coming years. Moreover, the market in North America is assessed to grab the largest share during the forecast period owing to the rising awareness associated with the availability of several treatment options, increase in healthcare spending and strong presence of prominent market players in the region. According to the National Health Expenditure Accounts (NHEA), total healthcare spending in the United States grew 4.6 percent in 2019, reaching $3.8 trillion or $11,582 per person. As a share of the nation's Gross Domestic Product, health spending accounted for 17.7 percent.

Get Strategic Analysis by Region Now: Request Free Sample PDF

Companies Dominating the Neuralgia Drugs Landscape

    • Pfizer, Inc.
      • Company Overview
      • Business Strategy
      • Key Product Offerings
      • Financial Performance
      • Key Performance Indicators
      • Risk Analysis
      • Recent Development
      • Regional Presence
      • SWOT Analysis
    • Novartis AG
    • Biogen Inc.
    • Cadila Healthcare Limited
    • Lundbeck Pharmaceuticals LLC
    • GlaxoSmithKline PLC
    • Teva Pharmaceutical Industries Ltd.
    • Mylan N.V.
    • Endo Pharmaceuticals Inc.
    • Teikoku Pharma USA, Inc.

Recent Developments

August 2021- Yuyu Pharma and Novartis Korea entered into an agreement in which Yuyu acquired the exclusive distribution rights for 3 prescription medicines, including Tegretol, a medicine containing carbamazepine used to treat conditions including epilepsy and trigeminal neuralgia.

  • Report ID: 3469
  • Published Date: Dec 24, 2024
  • Report Format: PDF, PPT
  • Get detailed insights on specific segments/region
  • Inquire about report customization for your industry
  • Learn about our special pricing for startups
  • Request a demo of the report’s key findings
  • Understand the report’s forecasting methodology
  • Inquire about post-purchase support and updates
  • Ask About Company-Level Intelligence Additions

Have specific data needs or budget constraints?

customer-service Inquiry Before Buying

Frequently Asked Questions (FAQ)

Neuralgia Drugs Market size is poised to grow at over 6.3% CAGR during the forecast period i.e., between 2025-2037.

The market growth is impelled by growing prevalence of trigeminal neuralgia and increasing incidence rate of diabetes around the world.

Asia Pacific industry is likely to hold largest revenue share by 2037, on the back of increasing occurrence of diabetes and rising elderly population in the region.

The major players in the market are Pfizer, Inc., Novartis AG, Biogen Inc., Cadila Healthcare Limited, Lundbeck Pharmaceuticals LLC, and others.

Neuralgia Drugs Market Report Scope

GET A FREE SAMPLE

FREE Sample Copy includes market overview, growth trends, statistical charts & tables, forecast estimates, and much more.

Connect with our Expert

Radhika Pawar
Radhika Pawar
Senior Research Analyst
Get a Free Sample

See how top U.S. companies are managing market uncertainty — get your free sample with trends, challenges, macroeconomic factors, charts, forecasts, and more.

Inquiry Before Buying Request Free Sample PDF

Copyright @ 2025 Research Nester. All Rights Reserved.

footer-bottom-logos